Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.

@article{Driscoll2011ComparisonOP,
  title={Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.},
  author={Timothy A. Driscoll and Haydar A. Frangoul and Eneida R Nemecek and Donald K Murphey and Lolie C. Yu and J. Blumer and Robert A. Krance and Alice Baruch and Ping Liu},
  journal={Antimicrobial agents and chemotherapy},
  year={2011},
  volume={55 12},
  pages={5780-9}
}
The current voriconazole dosing recommendation in adolescents is based on limited efficacy and pharmacokinetic data. To confirm the appropriateness of dosing adolescents like adults, a pharmacokinetic study was conducted in 26 immunocompromised adolescents aged 12 to <17 years following intravenous (IV) voriconazole to oral switch regimens: 6 mg/kg IV every 12 h (q12h) on day 1 followed by 4 mg/kg IV q12h, then switched to 300 mg orally q12h. Area under the curve over a 12-hour dosing interval… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Similar Papers

Loading similar papers…